Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: The example of C-reactive protein

Stephanie O. Keeling, Robert Landewé, Desiree Van Der Heijde, Joan Bathon, Maarten Boers, Patrick Garnero, Piet Geusens, Hani El-Gabalawy, Robert D. Inman, Virginia B. Kraus, Tore K. Kvien, Philip J. Mease, Mikkel Ostergaard, Chris Ritchlin, Silje W. Syversen, Walter P. Maksymowych

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Fingerprint

Dive into the research topics of 'Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: The example of C-reactive protein'. Together they form a unique fingerprint.

Medicine & Life Sciences